290 related articles for article (PubMed ID: 17000102)
1. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
2. De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II.
Carcache DA; Hörtner SR; Bertogg A; Binkert C; Bur D; Märki HP; Dorn A; Diederich F
Chembiochem; 2002 Nov; 3(11):1137-41. PubMed ID: 12404641
[No Abstract] [Full Text] [Related]
3. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
5. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
[TBL] [Abstract][Full Text] [Related]
6. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
7. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
[TBL] [Abstract][Full Text] [Related]
9. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
10. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
[TBL] [Abstract][Full Text] [Related]
13. Plasmepsin II inhibitory activity of alkoxylated and hydroxylated chalcones.
Sriwilaijaroen N; Liu M; Go ML; Wilairat P
Southeast Asian J Trop Med Public Health; 2006 Jul; 37(4):607-12. PubMed ID: 17121282
[TBL] [Abstract][Full Text] [Related]
14. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
15. Plasmepsins as potential targets for new antimalarial therapy.
Ersmark K; Samuelsson B; Hallberg A
Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.
Boss C; Richard-Bildstein S; Weller T; Fischli W; Meyer S; Binkert C
Curr Med Chem; 2003 Jun; 10(11):883-907. PubMed ID: 12678679
[TBL] [Abstract][Full Text] [Related]
17. A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
Salas E; Ramírez A; Otero-Bilbao A; Vázquez R; Reyes O; Mendiola J; Duarte CA; Otero-González A; Gutiérrez OA; Chávez MA
J Pharm Biomed Anal; 2004 Mar; 34(4):833-40. PubMed ID: 15019062
[TBL] [Abstract][Full Text] [Related]
18. High antiplasmodial activity of novel plasmepsins I and II inhibitors.
Dell'Agli M; Parapini S; Galli G; Vaiana N; Taramelli D; Sparatore A; Liu P; Dunn BM; Bosisio E; Romeo S
J Med Chem; 2006 Dec; 49(25):7440-9. PubMed ID: 17149873
[TBL] [Abstract][Full Text] [Related]
19. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M
ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859
[TBL] [Abstract][Full Text] [Related]
20. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
